ALLO
Allogene Therapeutics, Inc.
There isn't enough reported data to score ALLO yet.
ALLO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ALLO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ALLO PE Valuation
ALLO has no meaningful PE right now: it lost money over the past year.
ALLO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ALLO's losses to shrink, with revenue growing.
ALLO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.63 | +$0.34 |
| Q2 2026 | -$0.67 | +$0.43 |
| Q1 2026 | -$0.77 | +$0.45 |
| Q4 2025 | -$0.87 | +$0.45 |
| Q3 2025 | -$0.97 | +$0.57 |
| Q2 2025 | -$1.10 | +$0.49 |
| Q1 2025 | -$1.22 | +$0.55 |
| Q4 2024 | -$1.32 | +$0.75 |
ALLO is still losing money, but far less than before: $0.63 per share over the past year, against $2.45 at its worst in mid-2023.
ALLO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2024 | $22K | -58% |
| Q4 2023 | $21K | -55% |
| Q3 2023 | $43K | -12% |
| Q2 2023 | $44K | -49% |
| Q1 2023 | $52K | -15% |
| Q4 2022 | $47K | -7.8% |
| Q3 2022 | $49K | 0% |
| Q2 2022 | $86K | +95% |
ALLO's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1011% | N/A |
| Q1 2024 | -315927% | -125408 points |
| Q4 2023 | -405281% | -200230 points |
| Q3 2023 | -146453% | +21891 points |
| Q2 2023 | -182995% | -93933 points |
| Q1 2023 | -190519% | -59385 points |
| Q4 2022 | -205051% | -60163 points |
| Q3 2022 | -168345% | -9835 points |
ALLO's operating margin was −1011% last quarter, up 181984 points from the same quarter a year ago.
ALLO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$36.1M | -$6.2M |
| Q2 2026 | -$32.1M | +$6.9M |
| Q1 2026 | -$12.9M | +$40.1M |
| Q4 2025 | -$27.6M | +$9.4M |
| Q3 2025 | -$29.9M | +$14.6M |
| Q2 2025 | -$39.1M | +$24.5M |
| Q1 2025 | -$53M | +$2.9M |
| Q4 2024 | -$37M | +$16.9M |
ALLO has burned cash in almost every quarter: −$109M over the past year, against −$159M the year before.
ALLO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.2% | +17.2M shares |
| 1 year | +56% | +124M shares |
| 3 years | +106% | +178M shares |
| 5 years | +153% | +209M shares |
| Available history | +242% | +245M shares |
ALLO has 346M diluted shares, up 56% from a year ago.
ALLO Net Leverage
ALLO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ALLO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.2 | Oversold |
| Stochastic | 2.4 | Oversold |
ALLO's weekly RSI is 24 (oversold) and its Stochastic is 2 (oversold).
ALLO PE vs Healthcare Sector
ALLO has no meaningful PE right now: it lost money over the past year.
ALLO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.28 | 35% below |
| 20 week MA | $1.67 | 50% below |
| 50 week MA | $1.86 | 55% below |
| 100 week MA | $1.66 | 50% below |
| 200 week MA | $2.76 | 70% below |
ALLO is in a downtrend: it's below all five of its weekly moving averages, and 70% below its 200-week average.
ALLO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.3 | $27.3 | +3.8% |
| 2021 | $27.3 | $15.7 | -43% |
| 2022 | $15.7 | $5.96 | -62% |
| 2023 | $5.96 | $3.21 | -46% |
| 2024 | $3.21 | $2.19 | -32% |
| 2025 | $2.19 | $1.38 | -37% |
| 2026 YTD | $1.38 | $0.83 | -40% |
ALLO has finished five years in a row lower, and it's down 40% so far in 2026.